Restart for sustaining remission of rheumatoid arthritis in use of etanercept
Phase 4
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000008164
- Lead Sponsor
- Osaka City University Medical School
- Brief Summary
All 13 patients achieved LDA at final follow-up. Although joint damage progressed in patients using ETN on-demand, structural damage progression in the on-demand group was not significantly different from that in controls. On-demand use of ETN for flaring reduced disease activity but not structural damage in 50% of patients (though not significantly). However, inhibition of joint damage was achieved in 50% of patients after 2 years.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
Not provided
Exclusion Criteria
1. The patients with severe joint destruction of hands and feet because the evaluation of Sharp score will be impossible 2.The patients who take tacrolimus 3.The patients receiving glucocorticoid over 5mg/day
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of change of modified Sharp score at 24 months
- Secondary Outcome Measures
Name Time Method 1. The rate of change of DAS28 at 24 months 2. The rate of change of modified HAQ at 24 months 3. Safety profile